Two-Year Outcomes of Prostatic Artery Embolization for Symptomatic Benign Prostatic Hyperplasia: An International, Multicenter, Prospective Study.
Acute urinary retention
Benign prostatic hyperplasia
Embosphere® Microspheres
International Prostate Symptom Score (IPSS)
Lower urinary tract symptoms
Prostatic artery embolization
Quality of life
Sexual Health Inventory for Men (SHIM)
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
04 Sep 2024
04 Sep 2024
Historique:
received:
01
02
2024
accepted:
25
06
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
4
9
2024
Statut:
aheadofprint
Résumé
To describe clinical outcomes among patients with benign prostatic hyperplasia (BPH) 24 months following prostatic artery embolization (PAE). This was an international, multicenter, prospective trial of males with BPH with lower urinary tract symptoms (LUTS) or acute urinary retention (AUR) treated with PAE. The primary outcome was the 12 month change in the International Prostate Symptom Score (IPSS) for patients referred for bothersome LUTS, or urinary catheter independence for patients treated for AUR. Secondary outcome measures included changes in IPSS at 3 and 24 months, changes in quality of life (QoL), changes in the Sexual Health Inventory for Men (SHIM) questionnaire, technical success rate, and adverse events (AEs). Data were summarized using descriptive statistics. Four hundred seventy-eight consecutive patients underwent PAE (bothersome LUTS: N = 405; AUR: N = 73), mean age was 70 years. For patients treated for bothersome LUTS, mean total IPSS at baseline was 21.8 and decreased to 9.3, 10.6, and 11.2 at 3, 12, and 24 months following PAE, respectively (all p < 0.001); QoL at baseline was 4.7 and decreased to 2.0, 2.1, and 2.3 at 3, 12, and 24 months, respectively (all p < 0.001). The mean SHIM score at baseline and 12 months following PAE was 13.8 and 13.9, respectively. Of the 73 patients treated for AUR, 48 (65.8%) had their indwelling catheter removed within 3 months of PAE and remained catheter free at 24 months. Fifty-five patients (11.5%) experienced ≥ 1 AE and 10 (2.1%) experienced a serious AE. PAE is a safe and effective treatment for symptomatic BPH and LUTS. Level of Evidence Level 3 Trial registration ClinicalTrials.gov NCT03527589.
Identifiants
pubmed: 39230672
doi: 10.1007/s00270-024-03802-0
pii: 10.1007/s00270-024-03802-0
doi:
Banques de données
ClinicalTrials.gov
['NCT03527589']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Olivier Pellerin
(O)
Fabiane Barbosa
(F)
Peyman Borghei
(P)
Greg E Gin
(GE)
Edward Uchio
(E)
Adam N Plotnik
(AN)
James H Briggs
(JH)
Andrew MacDonald
(A)
Srini Tummala
(S)
Hemendra Navinchandra Shah
(HN)
Issam M Kably
(IM)
Keith Pereira
(K)
James Katrivesis
(J)
Keng Lim Ng
(KL)
Kirubahara Vaheesan
(K)
Mina Behdad
(M)
Sarah MacGill
(S)
Sarah Crosbie
(S)
Madita Gavrila
(M)
Susan Anthony
(S)
Lia Quezada
(L)
Ricardo Aleman
(R)
Cynthia Toot Ferguson
(CT)
Far Ahmed-Timms
(F)
Alexandra Edwards
(A)
Informations de copyright
© 2024. The Author(s).
Références
Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22(Suppl 1):1–6.
Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART II-surgical evaluation and treatment. J Urol. 2021;206(4):818–26.
doi: 10.1097/JU.0000000000002184
Bortnick E, Brown C, Simma-Chiang V, Kaplan SA. Modern best practice in the management of benign prostatic hyperplasia in the elderly. Ther Adv Urol. 2020;12:1756287220929486.
doi: 10.1177/1756287220929486
Carnevale FC, Moreira AM, de Assis AM, et al. Prostatic artery embolization for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: 10 years’ experience. Radiology. 2020;296(2):444–51.
doi: 10.1148/radiol.2020191249
de Assis AM, Moreira AM, Carnevale FC, et al. Role of ultrasound elastography in patient selection for prostatic artery embolization. J Vasc Interv Radiol. 2021;32(10):1410–6.
doi: 10.1016/j.jvir.2021.07.018
Abt D, Hechelhammer L, Mullhaupt G, et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ. 2018;361: k2338.
doi: 10.1136/bmj.k2338
Gao YA, Huang Y, Zhang R, et al. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate–a prospective, randomized, and controlled clinical trial. Radiology. 2014;270(3):920–8.
doi: 10.1148/radiol.13122803
Carnevale FC, Iscaife A, Yoshinaga EM, et al. Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective. Urodyn-Controll Anal Cardiovasc Interven Radiol. 2016;39(1):44–52.
doi: 10.1007/s00270-015-1202-4
Russo GI, Kurbatov D, Sansalone S, et al. Prostatic arterial embolization versus open prostatectomy: a 1-year matched-pair analysis of functional outcomes and morbidities. Urology. 2015;86(2):343–8.
doi: 10.1016/j.urology.2015.04.037
Insausti I, de Ocáriz AS, Galbete A, Capdevila F, Solchaga S, Giral P, Bilhim T, Isaacson A, Urtasun F, Napal S. Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia. J Vasc Int Radiol. 2020;31(6):882–90. https://doi.org/10.1016/j.jvir.2019.12.810 .
doi: 10.1016/j.jvir.2019.12.810
Tapping CR, Little MW, Macdonald A, et al. The STREAM Trial (prostatic artery embolization for the treatment of benign prostatic hyperplasia) 24 month clinical and radiological outcomes. Cardiovasc Interven Radiol. 2021;44(3):436–42.
doi: 10.1007/s00270-020-02702-3
Sapoval M, Thiounn N, Descazeaud A, et al. Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial. Lancet Reg Health Eur. 2023;31: 100672.
doi: 10.1016/j.lanepe.2023.100672
Pisco JM, Bilhim T, Costa NV, et al. Randomised clinical trial of prostatic artery embolisation versus a sham procedure for benign prostatic hyperplasia. Eur Urol. 2020;77(3):354–62.
doi: 10.1016/j.eururo.2019.11.010
Ray AF, Powell J, Speakman MJ, et al. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int. 2018;122(2):270–82.
doi: 10.1111/bju.14249
Qiu Z, Zhang C, Wang X, et al. Clinical evaluation of embolization of the superior vesical prostatic artery for treatment of benign prostatic hyperplasia: a single-center retrospective study. Wideochir Inne Tech Maloinwazyjne. 2017;12(4):409–16.
Salvador Hidalgo D, Bernardello Ureta M, Sbriglio M, et al. Prostatic artery embolization treatment for patients with benign prostatic hyperplasia who are permanent urinary catheter users ineligible for de-obstructive surgery. Actas Urol Esp (Engl Ed). 2021;45(7):481–5.
doi: 10.1016/j.acuro.2021.04.001
Pisco JM, Bilhim T, Pinheiro LC, et al. Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. J Vasc Interv Radiol. 2016;27(8):1115–22.
doi: 10.1016/j.jvir.2016.04.001
Rampoldi A, Barbosa F, Secco S, et al. Prostatic artery embolization as an alternative to indwelling bladder catheterization to manage benign prostatic hyperplasia in poor surgical candidates. Cardiovasc Interv Radiol. 2017;40(4):530–6.
doi: 10.1007/s00270-017-1582-8
Wang M, Guo L, Duan F, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms as a result of large benign prostatic hyperplasia: a prospective single-center investigation. Int J Urol. 2015;22(8):766–72.
doi: 10.1111/iju.12797
Bhatia S, Sinha VK, Harward S, et al. Prostate artery embolization in patients with prostate volumes of 80 mL or more: a single-institution retrospective experience of 93 patients. J Vasc Interv Radiol. 2018;29(10):1392–8.
doi: 10.1016/j.jvir.2018.05.012
Kenny AG, Pellerin O, Amouyal G, et al. prostate artery embolization in patients with acute urinary retention. Am J Med. 2019;132(11):e786–90.
doi: 10.1016/j.amjmed.2019.04.037
Franco JV, Jung JH, Imamura M, et al. Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis. Cochrane Database Syst Rev. 2021;7(7):CD013656.
Jung JH, McCutcheon KA, Borofsky M, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2022;3(3):CD012867.
Xu Z, Zhou Z, Mu Y, et al. An updated meta-analysis of the efficacy and safety of prostatic artery embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia. Front Surg. 2021;8:779571.
doi: 10.3389/fsurg.2021.779571
Lucas-Cava V, Sanchez-Margallo FM, Insausti-Gorbea I, Sun F. Comparative efficacy and safety of prostatic urethral lift versus prostatic artery embolization for benign prostatic hyperplasia: a systematic review and network meta-analysis. BJU Int. 2022;131(2):139–52.
doi: 10.1111/bju.15748
Uflacker A, Haskal ZJ, Bilhim T, et al. Meta-analysis of prostatic artery embolization for benign prostatic hyperplasia. J Vasc Interv Radiol. 2016;27(11):1686-1697.e8.
doi: 10.1016/j.jvir.2016.08.004
Xiang P, Guan D, Du Z, et al. Efficacy and safety of prostatic artery embolization for benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. Eur Radiol. 2021;31(7):4929–46.
doi: 10.1007/s00330-020-07663-2
Knight GM, Talwar A, Salem R, Mouli S. Systematic review and meta-analysis comparing prostatic artery embolization to gold-standard transurethral resection of the prostate for benign prostatic hyperplasia. Cardiovasc Interv Radiol. 2021;44(2):183–93.
doi: 10.1007/s00270-020-02657-5
Grosso M, Balderi A, Arno M, et al. Prostatic artery embolization in benign prostatic hyperplasia: preliminary results in 13 patients. Radiol Med. 2015;120(4):361–8.
doi: 10.1007/s11547-014-0447-3
Frandon J, Belaouni A, Pellerin O, et al. Efficacy and safety of prostate artery embolization for patients with lower urinary tract symptoms and indwelling urinary catheter: a retrospective multicenter study. Diagn Interv Imaging. 2022;103(12):601–6.
doi: 10.1016/j.diii.2022.07.002
Bilhim T, Costa NV, Torres D, Pinheiro LC, Spaepen E. Long-term outcome of prostatic artery embolization for patients with benign prostatic hyperplasia: single-centre retrospective study in 1072 patients over a 10-year period. Cardiovasc Interv Radiol. 2022;45(9):1324–36.
doi: 10.1007/s00270-022-03199-8
Abt D, Mullhaupt G, Hechelhammer L, et al. Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-yr outcomes of a randomised, open-label. Single-centre Trial Eur Urol. 2021;80(1):34–42.
Ayyagari R, Powell T, Staib L, et al. Prostatic artery embolization using 100–300-mum trisacryl gelatin microspheres to treat lower urinary tract symptoms attributable to benign prostatic hyperplasia: a single-center outcomes analysis with medium-term follow-up. J Vasc Interv Radiol. 2020;31(1):99–107.
doi: 10.1016/j.jvir.2019.08.005
Naidu SG, Narayanan H, Saini G, et al. Prostate artery embolization—review of indications, patient selection, techniques and results. J Clin Med. 2021;10(21):5139. https://doi.org/10.3390/jcm10215139 .
doi: 10.3390/jcm10215139
Amouyal G, Tournier L, De Margerie-Mellon C, et al. Safety profile of ambulatory prostatic artery embolization after a significant learning curve: update on adverse events. J Personal Med. 2022;12(8):1261. https://doi.org/10.3390/jpm12081261 .
doi: 10.3390/jpm12081261
Gil R, Shim DJ, Kim D, et al. Prostatic artery embolization for lower urinary tract symptoms via transradial versus transfemoral artery access: single-center technical outcomes. Korean J Radiol. 2022;23(5):548–54.
doi: 10.3348/kjr.2021.0934
McWilliams JP, Bilhim TA, Carnevale FC, et al. society of interventional radiology multisociety consensus position statement on prostatic artery embolization for treatment of lower urinary tract symptoms attributed to benign prostatic hyperplasia: from the society of interventional radiology, the cardiovascular and interventional radiological society of Europe, societe francaise de radiologie, and the British society of interventional radiology: endorsed by the Asia Pacific society of cardiovascular and interventional radiology, Canadian association for interventional radiology, Chinese college of interventionalists, interventional radiology society of Australasia, Japanese society of interventional radiology, and Korean society of interventional radiology. J Vasc Int Radiol. 2019;30(5):627-637.e1.
doi: 10.1016/j.jvir.2019.02.013
Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol. 2024;211(1):11–9.
doi: 10.1097/JU.0000000000003698